<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03243019</url>
  </required_header>
  <id_info>
    <org_study_id>2012_67</org_study_id>
    <secondary_id>2013-002800-15</secondary_id>
    <nct_id>NCT03243019</nct_id>
  </id_info>
  <brief_title>Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations</brief_title>
  <acronym>RAPAMALYMPH</acronym>
  <official_title>Evaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor Prognosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of Rapamycin in extended cervicofacial lymphatic malformations in
      pediatric patients. Rapamycin is administered oral for a 6 month period.

      The success rate is determined by volume reduction superior to 1/5e of the initial volume
      measured by MRI, impact on QOL and reduction of bleeding in case of mucosal involvement.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate to rapamycin</measure>
    <time_frame>At 3 months</time_frame>
    <description>Volumetric assessment by MRI. A response is considered as positive if volume decrease is superior to 1/5th of the initial volume.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetic of rapamycin response</measure>
    <time_frame>At 3, 6 and 12 months</time_frame>
    <description>MRI assessment of the volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of rapamycin on clinical symptoms</measure>
    <time_frame>At 3, 6 and 12 months</time_frame>
    <description>Clinical and fiberscopy evaluation by scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Quality of Life Inventory (PedsQL 4) Scales</measure>
    <time_frame>Baseline, at 3, 6 and 12 months</time_frame>
    <description>Assesses health-related quality of life among children with chronic and acute diseases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological response to rapamycin</measure>
    <time_frame>Baseline and at 6 months</time_frame>
    <description>biological effect of mTOR blockage by measuring pAKT, p70S6 kinase, pMEK, and VEGF C, VEGFR3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapamycin side effects</measure>
    <time_frame>Monthly during 1 years</time_frame>
    <description>Side effect assessment using the NCI-CTC 3.0 scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Lymphatic Malformation</condition>
  <condition>Pediatric</condition>
  <arm_group>
    <arm_group_label>SIROLIMUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rapamycin</intervention_name>
    <description>oral administration</description>
    <arm_group_label>SIROLIMUS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>cervicofacial MRI</description>
    <arm_group_label>SIROLIMUS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rapamycin dosage</intervention_name>
    <description>Biological dosage of Rapamycin level</description>
    <arm_group_label>SIROLIMUS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient from 1 to 18 years of age, presenting with poly-cystic suprahyoid or
             mediastinal lymphatic.

          -  with chronic pain or functional respiratory or swallowing impairment with a CDS score
             &lt; 8

          -  Curative treatment is not possible or associated with a high risk of morbidity
             ,mortality and functional and cosmetic impairment

          -  Karnofsky Score (&gt; 10 years of age) or Lansky score (≤10 years of age) &gt; 50%

          -  Biology

               -  Neutrophils count≥1.0 x 109/L

               -  Platelets count ≥ 100 x 109/L

               -  Hemoglobin ≥ 8 g/dL

               -  Bilirubin ≤ 1,5 ULN

               -  Transaminases &lt; 2,5 ULN

               -  Serum albumin ≥ 2 g/dL.

               -  LDL cholesterol &lt;160 mg/dL

               -  Triglycerides &lt; 150 mg/dL

          -  Negative test of pregnancy if relevant

          -  Social security affiliation

          -  At least 2 months after a previous procedure on the malformation

        Exclusion Criteria:

          -  Non-respect of inclusion criteria

          -  concomitant immuno-suppressor treatment

          -  renal failure

          -  Liver failure

          -  Digestive disease leading to rapamycin malabsorption

          -  uncontrolled or severe infectious disease

          -  Patients requiring treatment interfering with CYP3A4 isoenzyme (rifampicin, rifabutin,
             carbamazepine, phenobarbital, phenytoin) or inhibiting CYP3A4 isoenzyme's activity
             (ketoconazole, voriconazole, itraconazole, telithromycin, clarithromycin, Diltiazem,
             Verapamil, nicardipine, clotrimazole, fluconazole , troleandomycin, bromocriptine,
             cimetidine, danazol, protease inhibitors) -patients requiring treatment by cisapride
             and metoclopramide

          -  Concomitant administration of mTOR inhibitor

          -  Peanuts or soya allergy

          -  Impossibility to receive informed consent

          -  Absence of social security affiliation

          -  refusal to sign consent

          -  Ongoing pregnancy or breastfeeding

          -  refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Fayoux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Fayoux, MD</last_name>
    <phone>3 20 44 50 67</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre.fayoux@chru-lille.fr</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>August 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervico-facial</keyword>
  <keyword>rapamycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Lymphangioma</mesh_term>
    <mesh_term>Lymphatic Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

